AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases

 AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases

AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases

Shots:

  • Silence to receive $60M upfront, $20M equity investment, $10M as an option fee/ selected target, ~$140M as development milestones, ~$250M as commercial milestones for each target along with royalties on sales of the therapies
  • The multi-target alliance expected to initially work on 5 targets within the first 3yrs. of the collaboration with AstraZeneca to get an option to extend the collaboration for further 5 siRNA therapies targeting CV, renal, metabolic and respiratory diseases
  • The companies will collaborate during the discovery phase while AstraZeneca will lead clinical development and commercialization of molecules, developed during the collaboration. Silence will get an option to co-develop two programs starting from P-II

Click here ­to­ read full press release/ article | Ref: Silence Therapeutics  | Image: AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post